Experts from Memorial Sloan Kettering Cancer Center discuss updates from the 2026 European Lung Cancer Congress.
Jamie E. Chaft, MD
Advertisement
Jamie Chaft, MD, specializes in medical oncology, with a special focus on lung cancer. She practices primarily in New York, NY, and is affiliated with Memorial Sloan Kettering Cancer Center.
Articles by Jamie E. Chaft, MD
Chemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.
Jamie E. Chaft, MD, discusses biomarkers used to identify patients with lung cancer who would benefit from immunotherapy and the possibility for future biomarkers in this setting.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
2
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
3
Vilamakitug Meets Phase 2 Efficacy Criterion in Refractory Metastatic Colorectal Cancer
4
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
5